Advisory Board on Radiation and Worker Health (ABRWH or Advisory Board), National Institute for Occupational Safety and Health (NIOSH), 18584-18585 [E9-9332]
Download as PDF
<![CDATA[
18584
Federal Register / Vol. 74, No. 77 / Thursday, April 23, 2009 / Notices
sroberts on PROD1PC70 with NOTICES
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel. PAR–08–
261: Research on Emergency Medical
Services for Children.
Date: May 12–13, 2009.
Time: 9 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Virtual Meeting).
Contact Person: Suzanne Ryan, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3139,
Bethesda, MD 20892. (301) 435–1712.
ryansj@csr.nih.gov.
Name of Committee: Musculoskeletal, Oral
and Skin Sciences. Integrated Review Group.
Oral, Dental and Craniofacial Sciences Study
Section.
Date: May 27–28, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Hilton Alexandria Old Town,
1767 King Street, Salon A/B, Alexandria, VA
22314.
Contact Person: Tamizchelvi Thyagarajan,
PhD, Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4016K,
MSC 7814,Bethesda, MD 20892. 301–451–
1327. tthyagar@csr.nih.gov.
Name of Committee: Digestive, Kidney and
Urological Systems. Integrated Review
Group. Clinical and Integrative
Gastrointestinal Pathobiology Study Section.
Date: May 29, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Avenue Hotel Chicago, 160 E. Huron
Street, Chicago, IL 60611.
Contact Person: Mushtaq A. Khan, DVM,
PhD, Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2176,
MSC 7818, Bethesda, MD 20892. 301–435–
1778. khanm@csr.nih.gov.
Name of Committee: Cardiovascular and
Respiratory Sciences. Integrated Review
Group. Lung Injury, Repair, and Remodeling
Study Section.
Date: June 2–3, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Warwick Seattle Hotel, 401 Lenora
Street, Seattle, WA 98121.
Contact Person: Ghenima Dirami, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4112,
MSC 7814, Bethesda, MD 20892. 301–594–
1321. diramig@csr.nih.gov.
Name of Committee: Cell Biology
Integrated Review Group. Molecular and
Integrative Signal Transduction Study
Section.
VerDate Nov<24>2008
16:59 Apr 22, 2009
Jkt 217001
Date: June 2, 2009.
Time: 8 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: One Washington Circle Hotel, One
Washington Circle, NW., Washington, DC
20037.
Contact Person: Raya Mandler, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5134,
MSC 7840, Bethesda, MD 20892. (301) 402–
8228. rayam@csr.nih.gov.
Name of Committee: Integrative,
Functional and Cognitive Neuroscience.
Integrated Review Group. Neurobiology of
Learning and Memory Study Section.
Date: June 2–3, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: One Washington Circle Hotel, One
Washington Circle, NW., Washington, DC
20037.
Contact Person: Bernard F. Driscoll, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5184,
MSC 7844, Bethesda, MD 20892. (301) 435–
1242. driscolb@csr.nih.gov.
Name of Committee: Integrative,
Functional and Cognitive Neuroscience.
Integrated Review Group. Somatosensory and
Chemosensory Systems Study Section.
Date: June 2–3, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Melrose Hotel, 2430 Pennsylvania
Avenue, NW., Washington, DC 20037.
Contact Person: Daniel R. Kenshalo, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5182,
MSC 7844, Bethesda, MD 20892. 301–435–
1255. kenshalod@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel, Non-Human Primate
Reagent Resource.
Date: May 14, 2009.
Time: 1:30 p.m. to 3:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Rockledge 6700, 6700B Rockledge Drive,
3200, Bethesda, MD 20817.
Contact Person: Ellen S. Buczko, PhD,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institutes of Health/NIAID, 6700B
Rockledge Drive, MSC 7616, Bethesda, MD
20892–7616, 301–451–2676,
ebuczko1@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: April 15, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–9208 Filed 4–22–09; 8:45 am]
Advisory Board on Radiation and
Worker Health (ABRWH or Advisory
Board), National Institute for
Occupational Safety and Health
(NIOSH)
BILLING CODE 4140–01–M
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), and pursuant to the
requirements of 42 CFR 83.15(a), the
Centers for Disease Control and
Prevention (CDC), announces the
following meeting of the
aforementioned committee:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Dated: April 17, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–9349 Filed 4–22–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Board Meeting Times and Dates (All times
are Mountain Time):
9 a.m.–5 p.m., May 12, 2009.
9 a.m.–3:45 p.m., May 13, 2009.
Public Comment Times and Dates (All
times are Mountain Time):
7 p.m.–8 p.m., May 12, 2009.
E:\FR\FM\23APN1.SGM
23APN1
sroberts on PROD1PC70 with NOTICES
Federal Register / Vol. 74, No. 77 / Thursday, April 23, 2009 / Notices
4 p.m.–5 p.m., May 13, 2009.
Place: Holiday Inn Amarillo Hotel, 1911 I–
40 East, Amarillo, TX 79102; Phone: (806)
372–8741; Fax: (806) 372–7045. Audio
Conference Call via FTS Conferencing. The
USA toll-free dial-in number is 1–866–659–
0537 with a pass code of 9933701.
Status: Open to the public, limited only by
the space available. The meeting space
accommodates approximately 100 people.
Background: The Advisory Board was
established under the Energy Employees
Occupational Illness Compensation Program
(EEOICP) Act of 2000 to advise the President
on a variety of policy and technical functions
required to implement and effectively
manage the new compensation program. Key
functions of the Advisory Board include
providing advice on the development of
probability of causation guidelines which
have been promulgated by the Department of
Health and Human Services (HHS) as a final
rule; advice on methods of dose
reconstruction which have also been
promulgated by HHS as a final rule; advice
on the scientific validity and quality of dose
estimation and reconstruction efforts being
performed for purposes of the compensation
program, and advice on petitions to add
classes of workers to the Special Exposure
Cohort (SEC).
In December 2000, the President delegated
responsibility for funding, staffing, and
operating the Advisory Board to HHS, which
subsequently delegated this authority to the
CDC. NIOSH implements this responsibility
for CDC. The charter was issued on August
3, 2001, renewed at appropriate intervals,
and will expire on August 3, 2009.
Purpose: This Advisory Board is charged
with (a) providing advice to the Secretary,
HHS, on the development of guidelines
under Executive Order 13179; (b) providing
advice to the Secretary, HHS, on the
scientific validity and quality of dose
reconstruction efforts performed for this
program; and (c) upon request by the
Secretary, HHS, advise the Secretary on
whether there is a class of employees at any
Department of Energy facility who were
exposed to radiation but for whom it is not
feasible to estimate their radiation dose, and
on whether there is reasonable likelihood
that such radiation doses may have
endangered the health of members of this
class.
Matters To Be Discussed: The agenda for
the Advisory Board meeting includes: NIOSH
Program Status Update; Department of Labor
(DOL) Update; Department of Energy (DOE)
Update; Board Security Plan; Special
Exposure Cohort (SEC) Petitions for: Linde
Ceramics Plant (Residual Period); Standard
Oil Development Company of New Jersey;
Blockson Chemical Company (radon-related
dose reconstruction); and Dow Chemical
Company (Madison, Illinois); Special
Exposure Cohort (SEC) Petition Status
Updates; Work Group reports; Reports of the
Subcommittees on Dose Reconstruction
Reviews and Procedures Reviews; and Board
Future Plans and Meetings.
The agenda is subject to change as
priorities dictate.
In the event an individual cannot attend,
written comments may be submitted
VerDate Nov<24>2008
16:59 Apr 22, 2009
Jkt 217001
according to the policy provided below. Any
written comments received will be provided
at the meeting and should be submitted to
the contact person below well in advance of
the meeting.
Policy on Redaction of Board Meeting
Transcripts (Public Comment), (1) if a person
making a comment gives his or her name, no
attempt will be made to redact that name. (2)
NIOSH will take reasonable steps to ensure
that individuals making public comment are
aware of the fact that their comments
(including their name, if provided) will
appear in a transcript of the meeting posted
on a public Web site. Such reasonable steps
include: (a) A statement read at the start of
each public comment period stating that
transcripts will be posted and names of
speakers will not be redacted; (b) A printed
copy of the statement mentioned in (a) above
will be displayed on the table where
individuals sign up to make public comment;
(c) A statement such as outlined in (a) above
will also appear with the agenda for a Board
Meeting when it is posted on the NIOSH Web
site; (d) A statement such as in (a) above will
appear in the Federal Register Notice that
announces Board and Subcommittee
meetings. (3) If an individual in making a
statement reveals personal information (e.g.,
medical information) about themselves that
information will not usually be redacted. The
NIOSH FOIA coordinator will, however,
review such revelations in accordance with
the Freedom of Information Act and the
Federal Advisory Committee Act and if
deemed appropriate, will redact such
information. (4) All disclosures of
information concerning third parties will be
redacted. (5) If it comes to the attention of the
Designated Federal Officer (DFO) that an
individual wishes to share information with
the Board but objects to doing so in a public
forum, the DFO will work with that
individual, in accordance with the Federal
Advisory Committee Act, to find a way that
the Board can hear such comments.
Contact Person for More Information:
Theodore Katz, M.P.A., Executive Secretary,
NIOSH, CDC, 1600 Clifton Road, MS E–20,
Atlanta, GA 30333, Telephone (513)533–
6800, Toll Free 1(800) CDC–INFO, e-mail
ocas@cdc.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: April 16, 2009.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E9–9332 Filed 4–22–09; 8:45 am]
BILLING CODE 4163–18–P
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
18585
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Public Teleconference Regarding
Licensing and Collaborative Research
Opportunities for: A Double-Barreled
Attack: Azatoxins, A New Hope for
Treating Cancer
AGENCY: National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
Technology Summary
This technology describes a novel
class of Topoisomerase II (top2)
inhibitors that are useful in treating
cancer. Drugs that inhibit the top2
enzyme are among the most active
anticancer agents discovered. However,
many of the currently available
inhibitors produce toxic side effects,
have poor pharmacokinetics, or
eventually become ineffective because
malignant cells readily acquire
resistance. Therefore, there is a need for
developing new top2 inhibitor drugs
that will overcome these limitations.
Azatoxin and its derivatives, which
are derived by combining two parent
compounds etoposide and ellipticine,
are the first compounds rationally
designed as inhibitors of top2.
Azatoxins are also potent inhibitors of
tubulin polymerization. These two anticancer activities can be successfully
separated by synthesizing azatoxin
derivatives to yield compounds which
can be pharmacologically advantageous
against tumor proliferation. The
azatoxin platform represents an
unexploited class of top2 inhibitors that
could be developed into especially
potent chemotherapeutics.
Competitive Advantage of Our
Technology
Currently, several top2 inhibitors are
approved for clinical use; however, they
produce serious side effects. Etoposide,
for example, causes problems with
myelosuppression, drug resistance, and
has poor bioavailability. Moreover, it
appears to have carcinogenic properties
as it has been linked to the development
of acute myelogenous leukemia—an
effect also observed with mitoxantrone.
Anthracyclines, like doxorubicin, have
the same limitations as etoposide, but
they also possess cardiotoxic effects.
Azatoxins have the potential to be
developed into chemotherapeutics that
outperform these currently used top2
inhibitors.
Azatoxins have been substantially
characterized through years of preclinical research demonstrating that
E:\FR\FM\23APN1.SGM
23APN1
]]>Agencies
[Federal Register Volume 74, Number 77 (Thursday, April 23, 2009)]
[Notices]
[Pages 18584-18585]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-9332]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Advisory Board on Radiation and Worker Health (ABRWH or Advisory
Board), National Institute for Occupational Safety and Health (NIOSH)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), and pursuant to the requirements of 42
CFR 83.15(a), the Centers for Disease Control and Prevention (CDC),
announces the following meeting of the aforementioned committee:
Board Meeting Times and Dates (All times are Mountain Time):
9 a.m.-5 p.m., May 12, 2009.
9 a.m.-3:45 p.m., May 13, 2009.
Public Comment Times and Dates (All times are Mountain Time):
7 p.m.-8 p.m., May 12, 2009.
[[Page 18585]]
4 p.m.-5 p.m., May 13, 2009.
Place: Holiday Inn Amarillo Hotel, 1911 I-40 East, Amarillo, TX
79102; Phone: (806) 372-8741; Fax: (806) 372-7045. Audio Conference
Call via FTS Conferencing. The USA toll-free dial-in number is 1-
866-659-0537 with a pass code of 9933701.
Status: Open to the public, limited only by the space available.
The meeting space accommodates approximately 100 people.
Background: The Advisory Board was established under the Energy
Employees Occupational Illness Compensation Program (EEOICP) Act of
2000 to advise the President on a variety of policy and technical
functions required to implement and effectively manage the new
compensation program. Key functions of the Advisory Board include
providing advice on the development of probability of causation
guidelines which have been promulgated by the Department of Health
and Human Services (HHS) as a final rule; advice on methods of dose
reconstruction which have also been promulgated by HHS as a final
rule; advice on the scientific validity and quality of dose
estimation and reconstruction efforts being performed for purposes
of the compensation program, and advice on petitions to add classes
of workers to the Special Exposure Cohort (SEC).
In December 2000, the President delegated responsibility for
funding, staffing, and operating the Advisory Board to HHS, which
subsequently delegated this authority to the CDC. NIOSH implements
this responsibility for CDC. The charter was issued on August 3,
2001, renewed at appropriate intervals, and will expire on August 3,
2009.
Purpose: This Advisory Board is charged with (a) providing
advice to the Secretary, HHS, on the development of guidelines under
Executive Order 13179; (b) providing advice to the Secretary, HHS,
on the scientific validity and quality of dose reconstruction
efforts performed for this program; and (c) upon request by the
Secretary, HHS, advise the Secretary on whether there is a class of
employees at any Department of Energy facility who were exposed to
radiation but for whom it is not feasible to estimate their
radiation dose, and on whether there is reasonable likelihood that
such radiation doses may have endangered the health of members of
this class.
Matters To Be Discussed: The agenda for the Advisory Board
meeting includes: NIOSH Program Status Update; Department of Labor
(DOL) Update; Department of Energy (DOE) Update; Board Security
Plan; Special Exposure Cohort (SEC) Petitions for: Linde Ceramics
Plant (Residual Period); Standard Oil Development Company of New
Jersey; Blockson Chemical Company (radon-related dose
reconstruction); and Dow Chemical Company (Madison, Illinois);
Special Exposure Cohort (SEC) Petition Status Updates; Work Group
reports; Reports of the Subcommittees on Dose Reconstruction Reviews
and Procedures Reviews; and Board Future Plans and Meetings.
The agenda is subject to change as priorities dictate.
In the event an individual cannot attend, written comments may
be submitted according to the policy provided below. Any written
comments received will be provided at the meeting and should be
submitted to the contact person below well in advance of the
meeting.
Policy on Redaction of Board Meeting Transcripts (Public
Comment), (1) if a person making a comment gives his or her name, no
attempt will be made to redact that name. (2) NIOSH will take
reasonable steps to ensure that individuals making public comment
are aware of the fact that their comments (including their name, if
provided) will appear in a transcript of the meeting posted on a
public Web site. Such reasonable steps include: (a) A statement read
at the start of each public comment period stating that transcripts
will be posted and names of speakers will not be redacted; (b) A
printed copy of the statement mentioned in (a) above will be
displayed on the table where individuals sign up to make public
comment; (c) A statement such as outlined in (a) above will also
appear with the agenda for a Board Meeting when it is posted on the
NIOSH Web site; (d) A statement such as in (a) above will appear in
the Federal Register Notice that announces Board and Subcommittee
meetings. (3) If an individual in making a statement reveals
personal information (e.g., medical information) about themselves
that information will not usually be redacted. The NIOSH FOIA
coordinator will, however, review such revelations in accordance
with the Freedom of Information Act and the Federal Advisory
Committee Act and if deemed appropriate, will redact such
information. (4) All disclosures of information concerning third
parties will be redacted. (5) If it comes to the attention of the
Designated Federal Officer (DFO) that an individual wishes to share
information with the Board but objects to doing so in a public
forum, the DFO will work with that individual, in accordance with
the Federal Advisory Committee Act, to find a way that the Board can
hear such comments.
Contact Person for More Information: Theodore Katz, M.P.A.,
Executive Secretary, NIOSH, CDC, 1600 Clifton Road, MS E-20,
Atlanta, GA 30333, Telephone (513)533-6800, Toll Free 1(800) CDC-
INFO, e-mail ocas@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities, for both CDC and the Agency for Toxic Substances and
Disease Registry.
Dated: April 16, 2009.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. E9-9332 Filed 4-22-09; 8:45 am]
BILLING CODE 4163-18-P
